This article provides a comprehensive analysis of next-generation sequencing (NGS) for detecting microsatellite instability (MSI), a critical biomarker for immunotherapy response and Lynch syndrome identification.
This article provides a comprehensive analysis of next-generation sequencing (NGS) concordance between tissue and liquid biopsy across solid tumors, with emphasis on non-small cell lung cancer.
This article provides a comprehensive comparison of Illumina and Ion Torrent next-generation sequencing (NGS) platforms for cancer diagnostics, tailored for researchers, scientists, and drug development professionals.
This article provides a comprehensive overview of the critical performance metrics—analytical sensitivity and specificity—for Next-Generation Sequencing (NGS) panels in a clinical and research context.
This article provides a comprehensive analysis of next-generation sequencing (NGS) validation against the traditional gold standard, Sanger sequencing, for profiling cancer genes.
Tumor heterogeneity, encompassing spatial, temporal, and molecular diversity, poses a significant challenge for accurate cancer diagnosis, treatment selection, and monitoring.
Next-generation sequencing (NGS) has become a cornerstone of precision oncology, enabling comprehensive genomic profiling that guides diagnosis, prognostication, and therapeutic selection.
This article provides a comprehensive guide for researchers and drug development professionals seeking to optimize coverage uniformity in targeted next-generation sequencing (NGS).
The integration of next-generation sequencing (NGS) into clinical practice and drug development research is fraught with complex bioinformatics challenges that impact data accuracy, reproducibility, and clinical utility.
Formalin-fixed paraffin-embedded (FFPE) samples are invaluable for biomedical research, yet their degraded, low-input DNA poses significant challenges for next-generation sequencing (NGS).